AU6530794A - Method of treatment of diseases by deletion of t cells - Google Patents

Method of treatment of diseases by deletion of t cells

Info

Publication number
AU6530794A
AU6530794A AU65307/94A AU6530794A AU6530794A AU 6530794 A AU6530794 A AU 6530794A AU 65307/94 A AU65307/94 A AU 65307/94A AU 6530794 A AU6530794 A AU 6530794A AU 6530794 A AU6530794 A AU 6530794A
Authority
AU
Australia
Prior art keywords
cells
sea
deletion
cell
superantigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65307/94A
Other languages
English (en)
Inventor
John Kappler
Philippa Marrack
James E McCormack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
National Jewish Center for Immunology and Respiratory Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Jewish Center for Immunology and Respiratory Medicine filed Critical National Jewish Center for Immunology and Respiratory Medicine
Publication of AU6530794A publication Critical patent/AU6530794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU65307/94A 1993-04-08 1994-04-08 Method of treatment of diseases by deletion of t cells Abandoned AU6530794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4549493A 1993-04-08 1993-04-08
US045494 1993-04-08
PCT/US1994/003861 WO1994023734A1 (fr) 1993-04-08 1994-04-08 Procede de traitement d'une maladie par la suppression des lymphocytes t

Publications (1)

Publication Number Publication Date
AU6530794A true AU6530794A (en) 1994-11-08

Family

ID=21938212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65307/94A Abandoned AU6530794A (en) 1993-04-08 1994-04-08 Method of treatment of diseases by deletion of t cells

Country Status (5)

Country Link
EP (1) EP0692969A4 (fr)
JP (1) JPH08508752A (fr)
AU (1) AU6530794A (fr)
CA (1) CA2159891A1 (fr)
WO (1) WO1994023734A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012818A1 (fr) * 1990-02-23 1991-09-05 Immulogic Pharmaceutical Corporation Absence de faculte de reponse immune induite par superantigene

Also Published As

Publication number Publication date
EP0692969A1 (fr) 1996-01-24
JPH08508752A (ja) 1996-09-17
CA2159891A1 (fr) 1994-10-27
EP0692969A4 (fr) 1997-08-20
WO1994023734A1 (fr) 1994-10-27

Similar Documents

Publication Publication Date Title
Kupiec-Weglinski et al. Interleukin 2 receptor-targeted therapy—rationale and applications in organ transplantation
Abbas et al. Functional diversity of helper T lymphocytes
McCormack et al. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen.
Taylor et al. Suppressor cells in humoral immunity and tolerance
JPH04506512A (ja) 特定のｔ細胞集団の病原性応答により生じる疾患に対するワクチン接種および方法
EA002966B1 (ru) СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ВОСПАЛЕННОЙ ТОЛСТОЙ КИШКИ, СПОСОБ ВЫБОРА БЛОКАТОРА РЕЦЕПТОРА ЛИМФОТОКСИНА ( LT-b-R) И СПОСОБ ИНГИБИРОВАНИЯ ПЕРЕДАЧИ СИГНАЛА ЧЕРЕЗ LT-b-R
JPH10505482A (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
KR0183029B1 (ko) 내성을 유도하기 위한 모노클론 항체류
EP0722738A2 (fr) Vaccination et procédés contre des maladies issues de réponses pathogènes par des populations spécifiques de cellules T
US6326465B1 (en) Immunomodulatory polypeptides derived from the invariant chain of MHC class II
US20040110673A1 (en) Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US5643572A (en) Methods and compositions for the modulation of host immune response to an allergen
Pingel et al. Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope
JPH08500328A (ja) 突然変異したスーパー抗原の保護作用
WO1993012814A2 (fr) Vaccination et procedes contre des maladies resultant de reponses pathogenes de populations de lymphocytes t specifiques
US20040116338A1 (en) Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
AU686134B2 (en) Soluble T-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases
US6113903A (en) Peptides and methods against diabetes
AU6530794A (en) Method of treatment of diseases by deletion of t cells
US6413516B1 (en) Peptides and methods against psoriasis
AU697910C (en) Peptides and methods against psoriasis
Myers et al. Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization
Kirkham et al. New approaches for antirheumatic therapy
Barthel et al. Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis?
STROM et al. INTERLEUKIN-2—DIPHTHERIA TOXIN FUSION PROTEIN PROLONGS MURINE ISLET CELL ENGRAFTMENT" 2